Key result
Tailoring anticoagulant duration to risk factors guides effective secondary prophylaxis after VTE.
Why the study?
Individualization of anticoagulant duration after venous thromboembolism is crucial due to varying risk factors and recent evidence from subgroup analyses and new trials.
How should the duration of anticoagulants be tailored for secondary prophylaxis in patients with acute or recurrent venous thromboembolism?
How should the duration of anticoagulants be tailored for secondary prophylaxis in patients with acute or recurrent venous thromboembolism?
The duration of anticoagulation for secondary prophylaxis after venous thromboembolism should be individualized based on patient risk factors and biochemical markers.
May inform personalized VTE secondary prophylaxis decisions; extends reviews but leaves open RCT validation of risk thresholds.
While the most recent trend in secondary prophylaxis after venous thromboembolism has been toward a prolonged duration, it has become obvious that individualization according to risk factors is crucial. Subgroup analyses in a long-term follow-up of a previous trial, as well as new trials on patients with idiopathic thromboembolism, have now improved our base of evidence. Many studies on the influence of biochemical factors in the risk of recurrence have also been published recently. This review should be helpful in-the individual decision on how to tailor the duration of anticoagulation.
No takes yet. Share an insight, caveat, or question.
Sam Schulman (2000) conducted a review in acute or recurrent venous thromboembolism. Duration of anticoagulants was evaluated. Individualization of anticoagulant duration according to risk factors is crucial for secondary prophylaxis after venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: